Previous close | 56.80 |
Open | 56.70 |
Bid | 57.30 |
Ask | 58.45 |
Strike | 180.00 |
Expiry date | 2026-01-16 |
Day's range | 23.17 - 56.85 |
Contract range | N/A |
Volume | |
Open interest | 20 |
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
Catalent said on Friday the companies were in the process of gathering information to respond to the U.S. Federal Trade Commission's request received on May 2. Novo Holdings in February agreed to buy Catalent to boost output of the popular weight-loss drug Wegovy.